FDA ApprovalThe FDA has indicated positive results from PIVOT-PO along with data from prior clinical trials would be sufficient to approve tebi in cUTI and for limited use in acute pyelonephritis.
Financial StabilityCash of $53M, together with existing non-dilutive funding commitments, should provide OpEx runway into 2Q26.
Partnership MilestonesSpero's partner GlaxoSmithKline plc remains slated to pay the following potential additional milestone/royalty payments: up to a further $25M in clinical development-related milestones, up to $150M in commercial milestones based on initial sales, and up to $225M in sales-based milestones.